Guo Lanwei, Yang Funa, Yin Yulin, Liu Shuzheng, Li Peng, Zhang Xiaojun, Chen Defeng, Liu Yang, Wang Jian, Wang Kai, Zhu Yiming, Lv Qing, Wang Xiaoyu, Sun Xibin
Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Oncol. 2018 Dec 12;8:619. doi: 10.3389/fonc.2018.00619. eCollection 2018.
The burden of head and neck cancer in China is heavier, and studies have shown that it may be associated with HPV infection, especially high-risk HPV. We aimed to conduct a meta-analysis to estimate the high-risk HPV-16 prevalence of head and neck cancer in the Chinese population. The reports on HPV and head and neck cancer in a Chinese population published between Jan 1, 2006 and Oct 23, 2018 were retrieved via WANFANG/CNKI/MEDLINE/EMBASE databases. The pooled prevalence and corresponding 95% confidence intervals was calculated by a random-effect model. The meta-analysis included a total of 2,896 head and neck cancer cases from 28 studies. Overall, the pooled HPV-16 prevalence among head and neck cancer cases was 24.7% (20.2-29.3%) in China, 31.6% (21.7-41.5%) in oropharyngeal cancer, 28.5% (18.2-38.7%) in laryngeal cancer and 14.9% (10.1-19.7%) in oral cancer, 25.3% (14.8-35.8%) in fresh or frozen biopsies and 25.0% (19.5-30.5%) in paraffin-embedded fixed biopsies, 36.5% (17.9-55.1%) by E6/E7 region and 14.3% (6.4-22.1%) by L1 region of HPV gene. The highest HPV-16 prevalence was found in Central China. High prevalence of HPV-16 was found in the samples of Chinese head and neck cancers. Preventive HPV-vaccination may reduce the burden of HPV-related head and neck cancer in China.
中国头颈癌负担较重，研究表明其可能与HPV感染有关，尤其是高危型HPV。我们旨在进行一项荟萃分析，以估计中国人群头颈癌中高危型HPV-16的患病率。通过万方/知网/医学在线/荷兰医学文摘数据库检索了2006年1月1日至2018年10月23日期间发表的关于中国人群HPV与头颈癌的报告。采用随机效应模型计算合并患病率及相应的95%置信区间。该荟萃分析共纳入了来自28项研究的2896例头颈癌病例。总体而言，中国头颈癌病例中HPV-16的合并患病率为24.7%（20.2-29.3%），口咽癌为31.6%（21.7-41.5%），喉癌为28.5%（18.2-38.7%），口腔癌为14.9%（10.1-19.7%），新鲜或冷冻活检组织为25.3%（14.8-35.8%），石蜡包埋固定活检组织为25.0%（19.5-30.5%），HPV基因E6/E7区域检测为36.5%（17.9-55.1%），L1区域检测为14.3%（6.4-22.1%）。HPV-16患病率最高的地区是中国中部。在中国头颈癌样本中发现HPV-16的高患病率。预防性HPV疫苗接种可能减轻中国HPV相关头颈癌的负担。
